ArticleJournal of biological engineering2025
Lactate-related biomarkers in severe acute pancreatitis: insights from machine learning, molecular dynamics, and experimental validation.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute pancreatitis (AP) can be mild and self-limited, but it can also become severe acute pancreatitis (SAP) and lead to multi-organ dysfunction. It is still difficult to identify patients who may develop severe disease at an early stage. Lactate was once viewed only as a metabolic byproduct, but recent work shows that it also acts as a signaling molecule that links cellular energy status with immune control. Its role in the progression of AP is still not clear.
resultsTranscriptomic analysis showed clear differences in metabolism and immune features between SAP and non-severe AP (NSAP). Among lactate-related genes (LRGs), 24 were expressed at different levels. Three machine-learning methods identified CCNA2 and H2BC5 as possible diagnostic markers. Both genes had higher expression in SAP clinical samples. In vitro experiments showed that adding lactate increased CCNA2 and H2BC5 expression and raised inflammatory cytokine production. When these genes were knocked down, the inflammatory response decreased. This suggests that both genes are involved in lactate-driven inflammatory signaling. Molecular docking and simulation showed that the MDM2 inhibitor AMG-232 binds strongly to CCNA2, and the mTOR inhibitor Torin-1 binds strongly to H2BC5. Functional tests showed that Torin-1 reduced inflammation and oxidative stress in a sodium-taurocholate–induced cell model.
conclusionsThis study shows that CCNA2 and H2BC5 are candidate biomarkers for SAP. They are involved in important immune and metabolic pathways. AMG-232 and Torin-1 are possible therapeutic drugs. These findings give a molecular framework for early risk detection in AP and point to new options for targeted treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.